L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates
First Online: 20 April 2007 Received: 12 October 2006 Accepted: 18 March 2007 DOI:
10.1007/s00702-007-0727-3 Cite this article as: Kuoppamäki, M., Al-Barghouthy, G., Jackson, M. et al. J Neural Transm (2007) 114: 1147. doi:10.1007/s00702-007-0727-3 Summary
Most patients with Parkinson’s disease (PD) develop dyskinesia and other motor complications after prolonged L-dopa use. We now report on the relationship between L-dopa dose and the duration and severity of dyskinesia in L-dopa-primed MPTP-treated primates with marked nigral degeneration mimicking late stage PD. With increasing doses of L-dopa, locomotor activity increased and motor disability declined. The duration of dyskinesia following L-dopa administration increased dose-dependently, and showed a linear correlation with total locomotor activity. In addition, the time-course of dyskinesia paralleled closely that of locomotor activity in a dose-dependent manner. In contrast, severity of dyskinesia showed a non-linear correlation with total locomotor activity, low doses of L-dopa eliciting severe dyskinesia for short periods of time. The threshold for dyskinesia induction and the antiparkinsonian effects of L-dopa appear very similar in primed MPTP primates mimicking late stage PD. Reducing individual doses of L-dopa to avoid severe dyskinesia can markedly compromise the antiparkinsonian response. Our results extend the relevance of the dyskinetic MPTP-treated primate in studying the genesis of involuntary movements occurring in L-dopa treated patients with PD.
Keywords: Marmoset, Parkinson’s disease, priming, dyskinesia, involuntary movements References Agid, Y, Bonnet, AM, Ruberg, M, Javoy-Agid, F 1985 Pathophysiology of L-dopa-induced abnormal involuntary movements Psychopharmacology Suppl 2 145 159 PubMed Bédard, PJ, Di Paolo, T, Falardeau, P, Boucher, R 1986 Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [ 3H]spiperone binding Brain Res 379 294 299 CrossRef PubMed Bejjani, BP, Arnulf, I, Demeret, S, Damier, P, Bonnet, AM, Houeto, JL, Agid, Y 2000 Levodopa-induced dyskinesias in Parkinson’s disease: is sensitization reversible? Ann Neurol 47 655 658 CrossRef PubMed Boyce, S, Rupniak, NMJ, Steventon, MJ, Iversen, SD 1990 Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys Psychopharmacology 102 21 27 CrossRef PubMed Chase, TN, Oh, JD 2000 Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism Trends Neurosci 23 S86 S91 CrossRef PubMed Clarke, CE, Sambrook, MA, Mitchell, IJ, Crossman, AR 1987 Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) J Neurol Sci 78 273 280 CrossRef PubMed Di Monte, DA, McCormack, A, Petzinger, G, Janson, AM, Quik, M, Langston, WJ 2000 Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model Mov Disord 15 459 466 CrossRef PubMed Jenner, P, Rupniak, NM, Rose, S, Kelly, E, Kilpatrick, G, Lees, A, Marsden, CD 1984 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset Neurosci Lett 50 85 90 CrossRef PubMed Kostic, VS, Marinkovic, J, Svetel, M, Stefanova, E, Przedborski, S 2002 The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications Eur J Neurol 9 9 14 CrossRef PubMed Metman, LV, van den Munckhof, P, Klaassen, AA, Blanchet, P, Mouradian, MM, Chase, TN 1997 Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson’s disease Neurology 49 711 713 PubMed Mones, RJ, Elizan, TS, Siegel, GJ 1971 Analysis of L-dopa induced dyskinesias in 51 patients with parkinsonism J Neurol Neurosurg Psychiatry 34 668 673 CrossRef PubMed Mouradian, MM, Heuser, IJE, Baronti, F, Fabbrini, G, Juncos, JL, Chase, TN 1989 Pathogenesis of dyskinesias in Parkinson’s disease Ann Neurol 25 523 526 CrossRef PubMed Nutt, JG 2000 Clinical pharmacology of levodopa-induced dyskinesia Ann Neurol 47 S160 S166 PubMed Nutt, JG 2002 Motor fluctuations and dyskinesias Factor, SA Weiner, WJ eds. Parkinson’s disease Demos Medical Publishing New York 445 453 Nutt, JG, Woodward, WR 1986 Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients Neurology 36 739 744 PubMed Nutt, JG, Woodward, WR, Carter, JH, Gancher, ST 1992 Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon Arch Neuro 49 1123 1130 Olanow, CW, Schapira, AHV, Rascol, O 2000 Continuous dopamine-receptor stimulation in early Parkinson’s disease Trends Neurosci 23 S117 S126 CrossRef PubMed Pearce, RKB, Jackson, M, Smith, L, Jenner, P, Marsden, CD 1995 Chronic L-DOPA administration induces dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset ( Callithrix Jacchus) Mov Disord 10 731 740 CrossRef PubMed Pearce, RKB, Banerji, T, Jenner, P, Marsden, CD 1998 De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset Mov Disord 13 234 241 CrossRef PubMed Picconi, B, Centonze, D, Håkansson, K, Bernardi, G, Greengard, P, Fisone, G, Cenci, MA, Calabresi, P 2003 Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia Nature Neurosci 6 501 506 PubMed Rascol, O 2000 Medical treatment of levodopa-induced dyskinesias Ann Neurol 47 S179 S188 PubMed Schneider, JS 1989 Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage Pharmacol Biochem Behav 34 193 196 CrossRef PubMed Schrag, A, Quinn, N 2000 Dyskinesias and motor fluctuations in Parkinson’s disease: a community-based study Brain 123 2297 2305 CrossRef PubMed Smith, LA, Gordin, A, Jenner, P, Marsden, CD 1997 Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmoset Mov Disord 12 935 945 CrossRef PubMed Smith, LA, Jackson, MJ, Hansard, MJ, Maratos, E, Jenner, P 2000 Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration and brain exposure Mov Disord 18 487 495 CrossRef Smith, LA, Jackson, MJ, Al-Barghouthy, G, Rose, S, Kuoppamäki, M, Olanow, W, Jenner, P 2005 Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP treated drug-naïve primates Mov Disord 20 306 314 CrossRef PubMed